Clinical trials: Leukaemia
Cancer
Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90).
- Trial name
- NCT02973399
- Testing
- SNX-5422 plus ibrutinib
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Esanex Inc.
Leukemia
Role of Biomarkers in Disease Progression in Samples From Patients With Acute Myeloid Leukemia
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01500499
- Testing
- gene expression analysis, gene rearrangement analysis, polymerase chain reaction
- Volunteers
- 20 people
- Sponsor
- Children's Oncology Group
Acute Lymphoblastic Leukemia
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
- Trial name
- NCT00774332
- Testing
- CODOX-M
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Cooperative Study Group A for Hematology
Lymphoma, Neutropenia
Peripheral Stem Cell Transplantation to Prevent Neutropenia in Patients Receiving Chemotherapy for Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells.
- Trial name
- NCT00005787
- Testing
- epoetin alfa, filgrastim, recombinant flt3 ligand
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma
Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation
This pilot study has been designed to investigate the safety of pembrolizumab treatment for disease relapse following allogeneic stem cell transplant (alloSCT).
- Conditions
- Classical Hodgkin Lymphoma, B-cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT02981914
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Leukemia
A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma
Patients with relapsed or refractory leukemia often develop resistance to chemotherapy and some patients who relapse following CD19 directed therapy relapse with CD19 negative leukemia.
- Trial name
- PLAT-04 (NCT03244306)
- Testing
- Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Seattle Children's Hospital
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia
Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)
This is an open-label, multicentre study to characterize the safety and preliminary efficacy of the human anti CD19 antibody MOR00208 in adult subjects with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
- Trial name
- NCT01685021
- Testing
- MOR00208 (formerly Xmab5574)
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- MorphoSys AG
Leukemia, Lymphoma
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00423826
- Testing
- Busulfan, Cytarabine, Fludarabine phosphate
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia
Despite substantial progress in the treatment pediatric acute leukemia a significant number of children will experience primary or secondary resistance to the treatment.
- Trial name
- NCT01025778
- Testing
- Clofarabine for remission induction, Etoposide for remission induction, Cyclophosphamide for remission induction
- Where
- Sweden
- Volunteers
- 7 people
- Sponsor
- Lund University Hospital
Acute Lymphoblastic Leukemia
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
The protocol objective is providing adequate treatment and based on broad consensus in elderly patients with Acute Lymphoblastic Leukemia (ALL).
- Trial name
- NCT01366898
- Testing
- Dexamethasona, Idarubicine, ARA-C, Methotrexate
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission
This clinical study evaluates the efficacy and safety of maintenance therapy with BCL-2 inhibitors in elderly patients with acute myeloid leukemia (AML) in first complete remission.
- Trial name
- NCT05909293
- Testing
- Venclexta 100 MG Oral Tablet
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Growth factors, such as palifermin, may prevent chronic graft-versus-host disease caused by donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01233921
- Testing
- palifermin, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Martin, Paul
Immune System Diseases, Autoimmune Diseases
Clonal Hematopoiesis of Immunological Significance
Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic)…
- Conditions
- Immune System Diseases, Autoimmune Diseases, Inflammation, Autoinflammatory Diseases
- Trial name
- CHIS (NCT05969821)
- Testing
- observational cohort study
- Where
- France
- Volunteers
- 5,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Lymphocytic Leukemia (CLL)
Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries; it is stratified as a subtype of indolent lymphoid malignancy with a long but slowly progressive nature history.
- Trial name
- NCT02553304
- Volunteers
- 256 people
- Sponsor
- National Health Research Institutes, Taiwan
B-Cell Acute Lymphoblastic Leukemia, Adult
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
The purpose of this clinical trial is to learn if autologous bedside CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults.
- Trial name
- NCT07277504
- Testing
- CD19 CAR T cells
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The General Hospital of Western Theater Command
Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia
Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
This is the study to test combination regimen of Nilotinib and Ruxolitinib therapy for the treatment of patients with Philadelphia positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (ALL) who is resistant to…
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia
- Trial name
- NCT01914484
- Testing
- Nilotinib, Ruxolitinib
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University Health Network, Toronto
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Anxiety, Pain
Music and VR Effects on Pain, Anxiety, and Fear During Oral Mucositis Care in Leukaemic Children
Children undergoing leukaemia treatment are exposed to a wide range of chemotherapeutic agents and immunosuppressive therapies during treatment and are therefore at great risk for complications.
- Conditions
- Anxiety, Pain, Fear
- Trial name
- NCT06955338
- Testing
- Music intervention, Virtual reality
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Ege University
Hematologic Malignancy
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
- Trial name
- NCT02352558
- Testing
- BBI608, Dexamethasone, Bortezomib
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sumitomo Pharma America, Inc.